CD2AP

Chr 6

CD2 associated protein

Also known as: CMS

This gene encodes a scaffolding molecule that regulates the actin cytoskeleton. The protein directly interacts with filamentous actin and a variety of cell membrane proteins through multiple actin binding sites, SH3 domains, and a proline-rich region containing binding sites for SH3 domains. The cytoplasmic protein localizes to membrane ruffles, lipid rafts, and the leading edges of cells. It is implicated in dynamic actin remodeling and membrane trafficking that occurs during receptor endocytosis and cytokinesis. Haploinsufficiency of this gene is implicated in susceptibility to glomerular disease. [provided by RefSeq, Jul 2008]

Primary Disease Associations & Inheritance

Glomerulosclerosis, focal segmental, 3MIM #607832
UniProtFocal segmental glomerulosclerosis 3
1
Active trials
27
Pathogenic / LP
450
ClinVar variants
49
Pubs (1 yr)
0.0
Missense Z
0.41
LOEUF
Clinical SummaryCD2AP
🧬
Gene-Disease Validity (ClinGen)
focal segmental glomerulosclerosis 3, susceptibility to · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

2 total gene-disease associations curated

Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.24) despite low pLI — interpret in context.
📋
ClinVar Variants
27 Pathogenic / Likely Pathogenic· 247 VUS of 450 total submissions
💊
Clinical Trials
1 active or recruiting trial — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint
0.41LOEUF
pLI 0.230
Z-score 4.36
OE 0.24 (0.140.41)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint
0.00Z-score
OE missense 1.00 (0.911.10)
323 obs / 323.1 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.24 (0.140.41)
00.351.4
Missense OE1.00 (0.911.10)
00.61.4
Synonymous OE1.07
01.21.6
LoF obs/exp: 9 / 38.0Missense obs/exp: 323 / 323.1Syn Z: -0.61
LOFDN
DN
0.6839th %ile
GOF
0.6249th %ile
LOF
0.4627th %ile

This gene has evidence for multiple mechanisms of pathogenicity (loss-of-function and dominant-negative). The Badonyi & Marsh model scores dominant-negative highest among its predictions, but genomic evidence (constraint, ClinVar variant spectrum, and literature) most strongly supports loss-of-function (haploinsufficiency). Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

LOF48% of P/LP variants are LoF · LOEUF 0.41
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

450 submitted variants in ClinVar

Classification Summary

Pathogenic14
Likely Pathogenic13
VUS247
Likely Benign110
Benign57
Conflicting9
14
Pathogenic
13
Likely Pathogenic
247
VUS
110
Likely Benign
57
Benign
9
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
6
0
8
0
14
Likely Pathogenic
7
0
6
0
13
VUS
1
180
61
5
247
Likely Benign
0
11
63
36
110
Benign
0
0
55
2
57
Conflicting
9
Total1419119343450

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

CD2AP · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Literature
Landmark / reviewRecent case evidence